Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Psomagen Inc. (950200:KRX), powered by AI.
Psomagen Inc. is currently trading at ₩2,845. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Psomagen Inc. on Alpha Lenz.
Psomagen Inc.'s P/E ratio is -18.3.
“Psomagen Inc. trades at a P/E of -18.3 (undervalued) with modest ROE of -10.3%. 3Y revenue CAGR of 10.9% highlights clear growth momentum.”
Ask for details →Psomagen Inc. is a biotechnology company that specializes in genomic and bioinformatic services. With a focus on next-generation sequencing (NGS), Psomagen provides comprehensive solutions for genetic testing, research, and personalized medicine. The company's services are particularly impactful within the healthcare, pharmaceutical, and academic research sectors, offering vital insights into genetic data that facilitate groundbreaking scientific discoveries and personalized treatment plans. Psomagen serves a global clientele with a robust portfolio of services including whole genome sequencing, exome sequencing, and RNA sequencing, each designed to advance the understanding of genetic information. Headquartered in South Korea, Psomagen Inc. plays a significant role in the biotechnology industry, leveraging its expertise in genomics to contribute to the rapidly evolving field of precision medicine. This enhances the ability to diagnose, treat, and prevent diseases based on individual genetic profiles, solidifying its importance in modern healthcare research and development.
“Psomagen Inc. trades at a P/E of -18.3 (undervalued) with modest ROE of -10.3%. 3Y revenue CAGR of 10.9% highlights clear growth momentum.”
Ask for details →Psomagen Inc. (ticker: 950200) is a company listed on KRX in the Healthcare sector (Diagnostics & Research). It has approximately 96 employees. Market cap is $54.7B.
The current price is ₩2,845 with a P/E ratio of -18.35x and P/B of 2.01x.
ROE is -10.28% and operating margin is -3.81%. Annual revenue is $59.2B.